Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Baptiste Bachet

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
La Revue Du Praticien|March 8, 2022
[Contribution of neoadjuvant chemotherapy in rectal cancer]Jean-Baptiste Bachet
Bulletin Du Cancer|August 7, 2022
[Advanced GIST: Which treatments in 2022?]Léo Mas, Jean-Baptiste Bachet
La Revue Du Praticien|January 5, 2011
[Colorectal cancer: what progress can we anticipate in the next few years?]Jean-Baptiste Bachet, Philippe Rougier
The Application of Clinical Genetics|June 19, 2013
Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumorsJean-Baptiste Bachet, Jean-François Emile
La Revue Du Praticien|May 5, 2009
[Colon and rectal tumours]Jean-Baptiste Bachet, Gilles Lesur, Philippe Rougier
Current Opinion in Oncology|June 17, 2020
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectivesLéo Mas, Lilian Schwarz, Jean-Baptiste Bachet
Cancers|November 12, 2013
Treatment of pancreatic cancer: what can we really predict today?Jean-Baptiste Bachet, Raphael Marechal, Jean-Luc Van Laethem
Bulletin Du Cancer|June 18, 2021
[Neoadjuvant treatment for rectal cancer]Jean-Baptiste Bachet, Stéphane Benoist, Léo Mas, et al.
Bulletin Du Cancer|July 9, 2013
[What is the contribution of tumor response in colorectal cancer?]Jean-Baptiste Bachet, Xavier Paoletti, Laure Fournier, et al.
British Journal of Cancer|April 29, 2016
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'Simon Pernot, Jean-Baptiste Bachet, Alix Portal, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
La Revue Du Praticien|March 8, 2022
[Contribution of neoadjuvant chemotherapy in rectal cancer]Jean-Baptiste Bachet
Bulletin Du Cancer|August 7, 2022
[Advanced GIST: Which treatments in 2022?]Léo Mas, Jean-Baptiste Bachet
La Revue Du Praticien|January 5, 2011
[Colorectal cancer: what progress can we anticipate in the next few years?]Jean-Baptiste Bachet, Philippe Rougier
The Application of Clinical Genetics|June 19, 2013
Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumorsJean-Baptiste Bachet, Jean-François Emile
La Revue Du Praticien|May 5, 2009
[Colon and rectal tumours]Jean-Baptiste Bachet, Gilles Lesur, Philippe Rougier
Current Opinion in Oncology|June 17, 2020
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectivesLéo Mas, Lilian Schwarz, Jean-Baptiste Bachet
Cancers|November 12, 2013
Treatment of pancreatic cancer: what can we really predict today?Jean-Baptiste Bachet, Raphael Marechal, Jean-Luc Van Laethem
Bulletin Du Cancer|June 18, 2021
[Neoadjuvant treatment for rectal cancer]Jean-Baptiste Bachet, Stéphane Benoist, Léo Mas, et al.
Bulletin Du Cancer|July 9, 2013
[What is the contribution of tumor response in colorectal cancer?]Jean-Baptiste Bachet, Xavier Paoletti, Laure Fournier, et al.
British Journal of Cancer|April 29, 2016
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'Simon Pernot, Jean-Baptiste Bachet, Alix Portal, et al.
Pageof 18